Although less frequent than KRAS mutations, neuroblastoma ras viral oncogene homolog (NRAS) mutations occur in 5–9% of colorectal cancer cases, typically associated with tumor progression and resistance to anti-EGFR therapies in KRAS wild-type tumors [42]. This evidence concerns the gene NRAS and colorectal cancer.